Viatris Inc (VTRS)

Industry Drug Manufacturers - Specialty & Generic
This stock can be held in an Investment ISA and an Investment Account
Sell

$8.39

Buy

$8.55

arrow-down$-0.37 (-4.21%)

Prices updated at 14 May 2025, 11:10 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Mylan NV is a generic pharmaceutical manufacturer which develops, licenses, manufactures, markets and distributes generic, over-the-counter (OTC) products in a variety of dosage forms and therapeutic categories.
NASDAQ
arrow-up0.72%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Chairman
Mr. Robert J. Coury
CEO
Mr. Scott A. Smith
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
32,000
Head office
1000 Mylan Boulevard
Canonsburg
United States
15317
mobile
+1 724 514-1800
letter
InvestorRelations@Viatris.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Mr. Harry A. Korman
Independent Director
0.18m
Mr. Rajiv Malik
Director
1.30m
Dr. Michael Severino, M.D.
Independent Director
-
Mr. Frank D’Amelio
Independent Director
-
Ms. Elisha W. Finney
Independent Director
0.15m
Mr. James M. Kilts
Independent Director
0.15m
Mr. Wyllie Don Cornwell
Independent Director
0.15m
Mr. Mark W. Parrish
Vice Chairman of the Board
0.25m
Mr. Scott A. Smith
Director and Chief Executive Officer
1.02m
Ms. Melina E. Higgins
Chairman of the Board
0.23m
Ms. JoEllen Lyons Dillon
Independent Director
0.20m
Dr. Rogerio Vivaldi Coelho, M.B.A.,M.D.
Independent Director
-
Mr. Paul B. Campbell
Chief Accounting Officer and and Corporate Controller
-
Mr. Richard A. Mark, C.P.A.
Independent Director
0.20m
Mr. Leo Groothuis
Independent Director
0.11m
Ms. Theodora Mistras
Chief Financial Officer
-
Mr. Robert J. Coury
Chairman Emeritus
1.91m
Dr. Corinne Le Goff, Pharm.D.
Chief Commercial Officer
-
Mr. Brian Roman
Chief Legal Officer
0.79m

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
Vanguard Group Inc144,627,425
BlackRock Inc94,132,007
State Street Corp63,749,447
Davis Selected Advisers62,573,562
Davis Selected Advisers LP62,647,266

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
11 Nov 2024-
12 Sep 2024-
12 Sep 2024-
30 Aug 2024-
28 Aug 2024-
22 Aug 2024-
21 Aug 2024-
23 Aug 2024-
13 Jun 2024-
14 Jun 2024-
03 Jun 2024-
28 May 2024-
18 Apr 2024-
18 Apr 2024-
02 Apr 2024-
13 Mar 2024-
04 Mar 2024-
04 Mar 2024-
03 Mar 2024-
03 Mar 2024-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.